Skip to content
lifestyle.realie.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Transgene S.A.
Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field
September 24, 2026
Transgene & ProBioGen Expand Partnership with AGE1.CR.pIX Cell Line License
September 8, 2026
Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications
September 2, 2026
Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026
June 25, 2026
Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
June 22, 2026
Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases
May 26, 2026
Transgene’s Combined General Meeting of May 22, 2026
May 24, 2026
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026
May 21, 2026
Transgene Provides Business and Financial Update for Q1 2026
April 29, 2026
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
April 13, 2026
1
2
Next Page
→